Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-23
2011-10-04
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
08030284
ABSTRACT:
Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.
REFERENCES:
patent: 4343794 (1982-08-01), Podos et al.
patent: 4617299 (1986-10-01), Knepper
patent: 4652586 (1987-03-01), Nathanson
patent: 4757089 (1988-07-01), Epstein
patent: 4812448 (1989-03-01), Knepper
patent: 5075323 (1991-12-01), Fain et al.
patent: 5242943 (1993-09-01), Louis et al.
patent: 5260059 (1993-11-01), Acott et al.
patent: 5464866 (1995-11-01), Clark et al.
patent: 5545626 (1996-08-01), Stein et al.
patent: 5585401 (1996-12-01), Brandt et al.
patent: 6365576 (2002-04-01), Carr
patent: 6372249 (2002-04-01), Smith et al.
patent: 6489307 (2002-12-01), Phillips et al.
patent: 7176304 (2007-02-01), McSwiggen et al.
patent: 7294504 (2007-11-01), Wang
patent: 7462602 (2008-12-01), Schultz et al.
patent: 7521431 (2009-04-01), Reich et al.
patent: 7579457 (2009-08-01), Khvorova et al.
patent: 7592324 (2009-09-01), Shepard et al.
patent: 7592325 (2009-09-01), Jimenez et al.
patent: 2002/0055536 (2002-05-01), DeWitte et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2002/0165158 (2002-11-01), King
patent: 2004/0115641 (2004-06-01), Cowsert et al.
patent: 2004/0167090 (2004-08-01), Monahan et al.
patent: 2004/0198640 (2004-10-01), Leake et al.
patent: 2004/0209832 (2004-10-01), McSwiggen et al.
patent: 2004/0224405 (2004-11-01), Leake et al.
patent: 2004/0235031 (2004-11-01), Schultz et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2004/0266707 (2004-12-01), Leake et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0171039 (2005-08-01), McSwiggen et al.
patent: 2006/0058266 (2006-03-01), Manoharan et al.
patent: 2006/0094032 (2006-05-01), Fougerolles et al.
patent: 2006/0172963 (2006-08-01), Shepard et al.
patent: 2006/0172965 (2006-08-01), Shepard et al.
patent: 2007/0093435 (2007-04-01), Andrews et al.
patent: 2007/0167384 (2007-07-01), Leake et al.
patent: 2009/0326044 (2009-12-01), Shepard et al.
patent: 1 527 176 (2007-01-01), None
patent: 2406568 (2005-04-01), None
patent: WO 03/057840 (2003-07-01), None
patent: WO 03/070744 (2003-08-01), None
patent: 03/087367 (2003-10-01), None
patent: WO 2004/009794 (2004-01-01), None
patent: WO 2004/009796 (2004-01-01), None
patent: WO 2004/029212 (2004-04-01), None
patent: 2004/042024 (2004-05-01), None
patent: WO 2005/044976 (2005-05-01), None
patent: WO 2005/045037 (2005-05-01), None
patent: 2005/076998 (2005-08-01), None
patent: 2005/079815 (2005-09-01), None
patent: WO 2006/083945 (2006-08-01), None
patent: WO 2006/084217 (2006-08-01), None
patent: WO 2006/099353 (2006-09-01), None
Denkert et al (Oncogene 22: 8653-8661, 2003).
Gonzales et al (IOVS 41(2): 352-361, 2000).
Vittal et al (IOVS 46(8): 2857-2868, 2005).
Diskin al (IOVS 47(4): 1491-1499, 2006).
Rao et al (IOVS 42(5): 1029-1037, 2001).
Madsen (Documenta ophthalmologica. Advances in ophthalmology, (May 14, 1971) vol. 29, No. 2, pp. 345-349).
Herkel U et al., “Update on Topical Carbonic Anhydrase Inhibitors”, Current Opinion in Ophthalmology, Apr. 2001, vol. 12, No. 2, pp. 88-93.
Woodward et al., “The Inflow and Outflow of Anti-Glaucoma Drugs”, Trends in Pharmacological Sciences, vol. 25, No. 5, May 2004, pp. 238-241.
Jesús Pintor et al., “Adenosine Tetraphosphate, Ap4, a Physiological Regulator of Intraocular Pressure in Normotensive Rabbit Eyes,” The Journal of Pharmacology and Experimental Therapeutics, vol. 308, No. 2, pp. 468-473, 2004.
Office Action dated Jul. 14, 2008 in corresponding U.S. Appl. No. 11/360,305.
Office Action dated Jan. 29, 2009 in corresponding U.S. Appl. No. 11/360,305.
Abrams et al., “Comparison of Three Tonometers for Measuring Intraocular Pressure in Rabbits,” Invest Ophthalmol Vis Sci. Apr. 1996, 37(5):940-944.
Akashi et al., “Suppression of Gene Expression by RNA Interference in Cultured Plant Cells,” Antisense Nucleic Acid Drug Dev, 2001, 11(6):359-367.
Ambion, Tech Notes 10(4) and siRNA Target Finder (http://www.ambion.com/techlib/misc/siRNA—finder.html, available to the public) retrieved on May 1, 2008, siRNA target hit for SEQ ID No. 139 included.
Banerjee et al., “Control of Developmental Timing by Small Temporal RNAs: a Paradigm for RNA-mediated Regulation of Gene Expression,” Bioessays, 2002, 24(2):119-129.
Bhattacharya et al., “Cochlin Deposits in the Trabecular Meshwork of the Glaucomatous DBA/2J mouse,” Exp Eye Res., May 2005a 80(5):741-744.
Bhattacharya et al., “Proteomics Reveal Cochlin Deposits Associated with Glaucomatous Trabecular Meshwork,” J. Biol. Chem., Feb. 2005b, 18;280(7):6080-6084, Epub Dec. 3, 2004.
Bosher et al., “RNA Interference: Genetic Wand and Genetic Watchdog.” Nat Cell Biol, 2000, 2(2):E31-6.
Braasch et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,” Biochemistry, 2002, 41(14):4503-4510.
Brummelkamp et al., “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, American Association for the Advancement of Science, 2002, 296(5567):550-553.
Bunce et al., “Associations between the deletion polymorphism of the angiotensin 1-converting enzyme gene and ocular signs of primary open-angle glaucoma,” Graefes Arch Clin Exp Ophthalmol., Apr. 2005 243(4):294-299. Epub Oct. 13, 2004.
Caplen et al., “Specific inhibition of Gene Expression by Small Double Stranded RNAs in Invertebrate and Vertebrate Systems,” Proc. Natl. Acad. Sci. USA, 2001,98: 9742-9747.
Costagliola et al., “Effect of Oral Losartan Potassium Administration on Intraocular Pressure in Normotensive and Glaucomatous Human Subjects,” Exp Eye Res., Aug. 2000, 71(2):167-171.
Costagliola et al., “Effect of Oral Captopril (SQ 14225) on Intraocular Pressure in Man,” Eur. J. Opthalmol, Jan. 1995, 5(1):19-25.
Cullinane et al., “Renin-angiotensin System Expression and Secretory Function in Cultured human Ciliary Cody Nonpigmented Epithelium,” Br J Ophthalmol. Jun. 2002, 86(6):6766-83.
Elabashir et al., “Duplexes of 21-Nucleotide RNAs mediate RNA interference in Cultured Mammalian Cells,” Nature, May 24, 2001, 411(6836):494-498.
Elbashir et al., “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,” Genes Dev, 2001, 15(2):188-200.
Fattal et al., “Ocular Delivery of Nucleic Acids: Antisense Oligonucleotides, Aptamers and siRNA,” Advanced Drug Delivery Reviews, 2006, 58:1203-1223.
Fire et al., “Potent and Specific Genetic Interference by Double Stranded RNA in aCaenorhabditis elegans,” Nature, 1998, 391(6669):806-11.
Ge et al., “RNA Interference of Influenza Virus Production by Directly Targeting mRNA for Degradation and Indirectly Inhibiting all Viral RNA Transcription,” Proc Natl Acad Sci USA., 2003, 100(5):2718-2723.
Gil et al., “Induction of Apoptosis by the dsRNA-dependent Protein Kinase (PKR): Mechanism of Action,” Apoptosis, 2000, 5(2)107-114.
Grosshans et al., “Micro-RNAs: Small is Plentiful,” J Cell Bioi, 2002, 156(1):17-21.
Hammond et al., “Post-Transcriptional Gene Silencing By Double-Standed RNA,” Nature, 2001, 2:110-119.
Hara et al., “Bunazosin, a Selective Alpha1-Adrenoceptor Antagonist, as an Anti-glaucoma Drug: Effects on Ocular Circulation and Retinal Neuronal Damage,” Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
Khaw et al., “Glaucoma-1: Diagnosis,” BMJ, 2004a, 328:97-99.
Khaw et al., “Glaucoma-2: Treatment,” BMJ, 2004b, 328:156-158.
Kim et al., “Inhibition of Ocular Angiogenesis by Sirna Targeting Vascular Endothelial Growth Factor Pathway Genes Therapeutics Strategy for Herpetic Stromal Keratititis,” American Journal of Pathology, Dec. 2004, 165(6):2177-285.
Krutzfeldt e
de Buitrago Gonzalo González
Gascón Irene
Jiménez Ana I.
Roman José P.
Sesto Ángela
Brivanlou Margaret B.
King & Spalding LLP
Schnizer Richard
Sonnenfeld Kenneth H.
Sylentis S.A.U.
LandOfFree
Treatment of eye disorders characterized by an elevated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of eye disorders characterized by an elevated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of eye disorders characterized by an elevated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298775